marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
NeuroBo Pharmaceuticals Balance Sheet 2011-2024 | NRBO
Annual Balance Sheet NeuroBo Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-16.3 M | -10.1 M | -13.8 M | -9.52 M | -8.44 M | -24 M | 2.8 M | 420 K | - | - | - | ||
Long Term Debt |
136 K | - | 45 K | - | - | - | 8.68 M | - | - | - | - | - | - |
Long Term Debt Current |
67 K | - | 26 K | 24 K | 22 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 94 K | 1 K | 8.69 M | 1 K | 7.95 M | - | - | - | - |
Total Current Liabilities |
5.96 M | 11.8 M | 2.16 M | 3.7 M | 2.08 M | 11.9 M | 6.39 M | 4.12 M | - | - | - | - | - |
Total Liabilities |
6.1 M | 11.8 M | 2.2 M | 3.76 M | 2.18 M | 11.9 M | 15.1 M | 4.12 M | 16.9 M | 879 K | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-108 M | -95.8 M | -81.8 M | - | -36.9 M | -84.1 M | -60.5 M | -27.1 M | -12.4 M | -584 K | - | - | - |
Total Assets |
22.8 M | 33.5 M | 16.8 M | 11 M | 14.5 M | 19.7 M | 19 M | 24.8 M | 4.5 M | 348 K | - | - | - |
Cash and Cash Equivalents |
22.4 M | 33.4 M | 16.4 M | 10.1 M | 13.9 M | 19 M | 18.5 M | 24 M | 3.62 M | 317 K | - | - | - |
Book Value |
16.7 M | 21.8 M | 14.6 M | 7.2 M | 12.3 M | 7.77 M | 3.94 M | 20.6 M | -12.4 M | -531 K | - | - | - |
Total Shareholders Equity |
16.7 M | 21.8 M | 14.6 M | 7.2 M | 12.3 M | -13.3 M | 3.94 M | 20.6 M | -12.4 M | -531 K | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet NeuroBo Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
79 K | 98 K | 136 K | 153 K | - | - | - | - | - | 37 K | 45 K | 51 K | 58 K | 65 K | 70 K | 77 K | 82 K | 89 K | 94 K | 106 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
9.19 M | 9.81 M | 6.1 M | 4.88 M | 3.98 M | 11 M | 11.8 M | 1.62 M | 1.25 M | 1.53 M | 2.2 M | 1.95 M | 1.24 M | 1.01 M | 3.76 M | 3.76 M | 3.76 M | 3.76 M | 2.18 M | 2.18 M | 2.18 M | 2.18 M | 360 K | 11.9 M | 11.9 M | 11.9 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 4.12 M | 4.12 M | 4.12 M | 4.12 M | 8.92 M | 8.92 M | 8.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-131 M | -125 M | -108 M | -103 M | -99.1 M | -98.4 M | -95.8 M | -91.1 M | -88 M | -84.7 M | -81.8 M | -77.2 M | -73.8 M | -69.9 M | -66.5 M | -66.5 M | -66.5 M | -66.5 M | -36.9 M | -36.9 M | -36.9 M | -36.9 M | -15.6 M | -84.1 M | -84.1 M | -84.1 M | -60.5 M | -60.5 M | -60.5 M | -60.5 M | -27.1 M | -27.1 M | -27.1 M | -27.1 M | -12.4 M | -12.4 M | -12.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
22.1 M | 28.8 M | 22.8 M | 26.4 M | 29.2 M | 31.5 M | 33.5 M | 7.56 M | 10.1 M | 13.5 M | 16.8 M | 8.08 M | 10.7 M | 14.2 M | 11 M | 11 M | 11 M | 11 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 3.82 M | 19.7 M | 19.7 M | 19.7 M | 19 M | 19 M | 19 M | 19 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 4.49 M | 4.49 M | 4.49 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
21.7 M | 27.9 M | 22.4 M | 25.8 M | 28.7 M | 30.8 M | 33.4 M | 6.36 M | 8.85 M | 11.6 M | 16.4 M | 6.98 M | 9.51 M | 13 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 2.84 M | 19 M | 19 M | 19 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 24 M | 24 M | 24 M | 24 M | 3.62 M | 3.62 M | 3.62 M | - | 317 K | - | - | - | 3 K | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
13 M | 18.9 M | 16.7 M | 21.6 M | 25.2 M | 20.5 M | 21.8 M | 5.94 M | 8.83 M | 11.9 M | 14.6 M | 6.12 M | 9.48 M | 13.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 3.46 M | 7.77 M | 7.77 M | 7.77 M | 3.94 M | 3.94 M | 3.94 M | 3.94 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | -4.43 M | -4.43 M | -4.43 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
13 M | 18.9 M | 16.7 M | 21.6 M | 25.2 M | 20.5 M | 21.8 M | 5.94 M | 8.83 M | 11.9 M | 14.6 M | 6.12 M | 9.48 M | 13.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | -13.3 M | 7.77 M | 7.77 M | 7.77 M | 25 K | 3.94 M | 3.94 M | 3.94 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | -12.4 M | -12.4 M | -12.4 M | - | -531 K | - | - | - | -264 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency